Life Sciences · Biotechnology
Biotech Contingent Workforce Solutions
Senior regulated-industry expertise on terms a clinical-stage company can justify, without building permanent infrastructure ahead of the milestone.
Biotech contingent workforce solutions exist because the staffing problem in emerging biotech is the opposite of the one in large pharma. You do not need forty contract quality specialists. You need one very experienced quality leader for two days a week, a regulatory strategist for the pre-IND meeting, and a CMC lead who has taken a comparable modality through the same transition before. Viltis structures that access, senior and part-time and scoped to a milestone, while keeping the engagements compliant and reportable instead of scattered across a set of personal consulting arrangements.
Overview
Milestones, not headcount plans
Biotech resourcing is driven by events with dates attached and funding attached to them: an IND filing, a first-in-human study, a Series C raise, a partnership diligence process, an IPO readiness review, or a technology transfer to a CDMO. Each requires expertise that is essential for a quarter and unnecessary for the two that follow.
Hiring permanently against those peaks is how young companies end up with a quality department that outgrew its purpose before the first commercial batch. Hiring nothing is how they end up with an IND that a consultant has to rescue at short notice.
Overview
The fractional senior model
The most valuable contract engagements in biotech are usually fractional leadership rather than execution capacity. A head of quality who has built a system from nothing three times before, engaged for two days a week, will produce a better outcome than a full-time hire learning the modality on your timeline.
We structure those engagements with defined scope, deliverables, and a stated expectation about what happens as the company grows, including the point at which the role should convert to permanent. Fractional leadership that quietly becomes indefinite is a governance problem for a board, not a workforce strategy.
Fractional head of quality to build the quality system and prepare for GMP manufacture
Regulatory strategy leadership through pre-IND, IND, and agency meeting preparation
CMC leadership for process development, comparability, and CDMO technical transfer
Clinical operations leadership for first-in-human study startup and CRO oversight
Pharmacovigilance system establishment and qualified person arrangements as trials begin
Overview
Overseeing the outsourced network
Emerging biotech runs on CDMOs, CROs, and specialist vendors. The internal team is small, and its main job is oversight rather than execution. That makes vendor oversight the contract role that matters most in the company, and it is frequently the one that is filled last.
We resource oversight specifically: people who have audited CDMOs, managed CRO performance, and know what a technical transfer looks like when it is going wrong. The program also brings your consulting and CRO spend into the same visibility as your staffing spend, which matters when the board asks where the burn is going.
Overview
Scaling up, and scaling back
Biotech workforce planning has to contemplate both directions. A positive readout means rapid scaling into GMP manufacturing, commercial readiness, and a much larger regulatory footprint. A failed endpoint or a funding gap means contraction, sometimes quickly.
A contingent-heavy structure keeps both options open, provided the engagements carry clear terms and are not informal arrangements that turn out to be hard to unwind. We design for that from the start, because it is the situation many of these programs eventually face.
Overview
Diligence-ready from the start
Partnering and financing diligence looks closely at how a company has resourced its regulated activities. Undocumented consultant arrangements, unclear worker classification, and consultants holding quality system access with no training record are all findings that slow a process at exactly the wrong moment.
Running contract engagements through a proper program costs little while the company is small, and it is much harder to retrofit at Series C.
Benefits
What emerging biotech companies get
Senior expertise at a defensible cost
Fractional engagement gives access to leaders who have done the transition before, without a permanent salary the current stage cannot justify.
Resourcing tied to milestones
Capacity is scoped to the IND, the transfer, or the raise, so spend tracks the event rather than persisting after it.
Vendor oversight actually staffed
CDMO and CRO oversight is resourced with people who have done it, instead of being absorbed by a founder or a stretched internal lead.
Optionality in both directions
Cleanly structured engagements let the company scale fast on positive data and contract without protracted unwinding if plans change.
Diligence-ready documentation
Classification, training, and access records for consultants exist from the start, which removes a common source of friction in partnering and financing diligence.
One view of external spend
Consulting, CRO, and contract staffing spend appear together, so the board can see where external effort is going.
FAQ
Biotech contingent workforce FAQs
We are twenty people. Is a workforce program premature?
A full MSP and VMS deployment probably is. Getting classification, engagement terms, training, and access controls right for the consultants you already use is not. That costs little now and is expensive to reconstruct later. We scope accordingly, and will say so if the lighter option is the right one.
How do you handle consultants who are already engaged informally?
We review the existing arrangements for classification exposure, contract adequacy, and access appropriateness, then transition them onto proper terms. We do that with the people involved, not around them, since most are long-standing advisors the company wants to keep.
Can a fractional quality lead satisfy regulatory expectations?
Fractional and part-time arrangements are common and workable, provided the responsibilities, authority, and availability are documented and the person is reachable when decisions are needed. Where a named role carries specific regulatory requirements, those requirements govern the arrangement.
What happens to these engagements if we are acquired?
Clearly structured contract engagements are considerably easier to assign, terminate, or transition than informal arrangements, which is one reason we document them properly. The specific treatment depends on the transaction and the contract terms.
Do you support cell and gene therapy companies?
Yes. Those programs bring particular demand for expertise in comparability, potency assay development, chain of identity and custody, and manufacturing at limited scale, and supplier qualification is weighted toward suppliers with real access to that talent.
Continue
Related industry programs
Ready to talk through your program?
Bring us your current spend, supplier list, and compliance obligations. We will show you what a technology-enabled contingent workforce program would look like for your organization.